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Abstract
Background: The aim of our study was to evaluate the antimicro-
bial resistance rates among pathogen microorganisms especially co-
listin resistant rates of Acinetobacter baumannii in intensive care unit 
(ICU)-acquired infections and to determine infection-specific correct 
treatment strategies.
Methods: The data of adult and newborn infant patients diagnosed 
with ICU-acquired infection in a tertiary education and research hos-
pital in Bursa in 2014 and 2016 were analyzed, retrospectively. 
Results: Acinetobacter baumannii was the most frequent pathogen 
of ICU-acquired infections in 2014 and 2016. There was a significant 
increase in colistin (CO) resistance rates in A. baumanii (0.0%-6.8%). 
A significant increase in CO, cefepime (FEP), ciprofloxacin (CIP) resis-
tance rates was established in all gram negative bacteria (0.0%-7.9%, 
50.0%-91.9%, 54.7%-74.6%), respectively. A significant increase in 
the rate of detection of A. baumanii as the pathogen microorganism 
in respiratory tract infection (RTI) was established (53.9% -79.5%). In 
addition, the average ventilator-associated pneumonia (VIP) infection 
rate also increased in 2016 compared to 2014 (VIP rate 2014: 7.12, 
2016: 7.45, per 1000 ventilator days). A significant decrease in the rate 
of detection of all gram negative microorganisms in the surgical site 
infection (SSI), and a significant increase in the rate of detection of all 
gram positive microorganisms in the SSI was determined. 
Conclusion: Increased antimicrobial resistance, especially increased 
colistin resistance rates in ICU-acquired infections, necessitates the 
creation of new strategies in empirical therapy. Detection of antimi-
crobial resistance profiles of local and infectious pathogen microorga-
nisms in ICUs is a good guide for correct antimicrobial management.
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Introduction
The frequent use of broad spectrum antibiotics in 
intensive care unit (ICU), leads to increased rates 
of antimicrobial resistance and more frequent oc-
currence of multidrug-resistant microorganisms [1-
3]. Increased antimicrobial resistance in ICU- acqui-
red pathogens complicates treatment and limits 
new treatment options [4-6]. Nowadays colistin is 
frequently used as an effective antibiotic in ICU-
acquired infections caused by multiresistant gram-
negative bacteria, but colistin resistance is also ob-
served to be increasing in recent years [7-9]. In the 
management of antimicrobial resistance in ICUs; 
it is necessary to optimize specific diagnosis and 
treatment of infections. In addition, strategies for 
selection of antibiotics, optimization of dose and 
duration, prevention of the passage of resistant 
pathogenic microorganisms to the patient through 
correct infection control measures need to be deve-
loped [10]. Microbiologists, clinicians, and infection 
control staff must work together to identify specific 
common bacteria and antibiotic resistance profiles 
in ICUs to select the right antibiotics for treatment 
[4, 11].
The aim of this study was to evaluate the antimi-
crobial resistance rates especially colistin resistance 
rates of pathogen microorganisms in ICU-acquired 
infections and to determine infection-specific co-
rrect treatment strategies.
Materials and methods
Data collection
Bursa Yuksek Ihtisas Education and Research Hospi-
tal which is serviced 3 million population in Turkey, 
and is a tertiary care hospital with total of 147 ICU-
patient beds including cardiovascular surgery (CVS), 
general surgery, internal medicine, cardiology, pe-
diatry, newborn and reanimation departments. In 
our study, the data of adult and newborn infants 
diagnosed with ICU-acquired infection in 2014 and 
2016 were analyzed retrospectively. ICU-acquired 
infections were determined according to the criteria 
of Centers for Disease Control and Prevention (CDC) 
guidelines for patients after length of ICU stay of 
48 hours. ICU-acquired infections were categorized 
according to CDC criteria as blood stream infection 
(BSI), respiratory tract infection (RTI), urinary tract 
infection (UTI), surgical site infection (SSI), skin and 
soft tissue infection (SSTI) and central nervous sys-
tem infection (CNSI).
Microbiological tests
Bacterial and fungal cultivation were made from 
clinical samples (blood, cerebrospinal fluid, urine, 
wound, tissue, tracheal aspirate, etc.) of the ICU 
patients in microbiology laboratory. Positive blood 
and cerebrospinal fluid cultures were detected by 
automated blood culture system (BACTEC 9240 
Blood Culture System; Becton Dickinson Bioscien-
ces). Identification and antibiograms of gram-po-
sitive and gram-negative bacteria and yeast fungi 
were determined from the pure isolates obtained 
from the cultures on the automated device (Vitek 
2, bioMérieux, USA). All antibiotic resistance va-
lues  were determined based on current EUCAST 
minimal inhibitor concentration (MIC) limit values. 
Amikacin (AN), ampicillin (AM), gentamicin (GN), 
imipenem (IMP), piperacillin-tazobactam (TPZ), FEP, 
cefotaxime (CTX), trimethoprim-sulfamethoxazole 
(SXT), meropenem (MEM), ceftazidim (CAZ), ce-
ftriaxone (CRO), tetracycline (TE), cefoxitin (FOX), 
teicoplanin (TEC), vancomycin (VA), linezolid (LNZ) 
and colistin (CO). 
Statistical analysis
The data were analyzed using the Fisher-exact Chi 
square test and the Pearson Chi square test by 
the SPSS program version 21.0. Statistically signifi-
cant difference was accepted as p<0.05-95% and 
p<0.01-99%.
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Results
The distribution of all pathogen microorganisms 
according to period of detection was shown in 
ICU-acquired infections (Table 1). Acinetobacter 
baumannii was the most frequent pathogen detec-
ted in ICU- acquired infections in 2014 and 2016, 
among gram-negative bacteria, whereas among 
gram-positive bacteria coagulase-negative Stapylo-
coccus (CNS), and Candida albicans among Candida 
spp. was the most frequent isolates.
Antibiotic resistance rates of gram-negative 
pathogens in ICU-acquired infections were compa-
red between 2014 and 2016 (Table 2, 3). 
There was a significant increase in CO resistance 
rates in A. baumanii (0.0%-6.8%, p <0.05). There 
was a significant increase in GN resistance rates in 
Klebsiella pneumoniae (41.9% -80.3%, p <0.01). 
A significant decrease in TPZ resistance rates was 
found in Pseudomonas aeruginosa (65.1% - 31.4%, 
p<0.01).
A significant increase in CO and FEP resistance 
rates was established in all gram negative bacteria 
(0.0%-7.9%, 50.0% -91.9%, p<0.01). CIP resistan-
ce rates were also significantly increased (54.7% 
-74.6%, p<0.05). The increase of AM, GN, CAZ, 
TPZ, IMP, MEM, and SXT resistance ratios were not 
statistically significant. The decrease in CTX and 
CRO resistance ratios was not statistically signifi-
cant. AN resistance rate did not change.
Antibiotic resistance rates of gram-positive patho-
gens in ICU-acquired infections were compared bet-
ween 2014 and 2016 (Table 4).
There was a significant decrease in GN resistance 
of CNS (76.0%-42.1%, p<0.05) and a significant 
decrease in FOX resistance in Stapylococcus aureus 
(100.0% -75.0%, p<0.05).
A significant decrease in FOX and GN resistan-
ce was determined in all gram positive bacteria 
(100.0% -75.0%, 76.0% -42.1%, p<0.05). The de-
crease of LNZ, SXT, VA and TE resistance ratios was 
not statistically significant, and the increase of AM 
resistance was not statistically significant.
Table 1.  Distribution of all recovered pathogens from 
ICU-acquired infections over the 2-year 
(2014 & 2016).
Microorganism
2014 2016 
n % n %
Gram Negative Bacteria
Acinetobacter baumannii 89 26.0 73 25.4
Acinetobacter spp. 53 15.5 6 2.1
Pseudomonas aeruginosa 43 12.5 35 12.2 
Klebsiella pneumoniae 31 9.0 69 24
Escherichia coli 13 3.8 23 8.0 
Enterobacter aerogenes 6 1.8 1 0.3 
Pseudomonas spp. 5 1.5 3 1.0 
Klebsiella spp. 5 1.5 0 66.47
Enterobacter spp. 3 0.9 3 1.0 
Serratia marcescens 3 0.9 2 0.7 
Enterobacter cloacae 2 0.6 3 1.0 
Proteus mirabilis 1 0.3 4 1.4 
Stenotrophomonas maltophilia 1 0.3 1 0.3 
Citrobacter spp. 0 2 0.7 
Burkholderia cepacia 0 1 0.3 
Morganella morganii 0 1 0.3 
Salmonella spp. 0 1 0.3 
Klebsiella oxytoca 0 0
Other 0 0
Gram Negative Bacterias
Fermantatives 65 19 111 38.5
Non-Fermantatives 190 55.5 117 40.6 
Total 255 74.6 228 79.2 
Gram Positive Bacteria
CNS 25 7.3 19 6.6 
Staphylococcus aureus 19 5.5 12 4.3 
Enterococcus faecalis 8 2.3 7 2.5 
Enterococcus faecium 2 0.6 6 2.1 
Enterococcus spp. 6 1.8 2 0.7 
Streptococcus pneumoniae 1 0.3 0
Gram Positive Bacterias 61 17.8 46 15.9 
All Candida spesies
Candida spp. 13 3.8 7 2.5 
Candida albicans 9 2.6 3 1.0 
Candida glabrata 0 1 0.3 
Candida parapsilosis 3 0.9 2 0.7 
Candida tropicalis 1 0.3 1 0.3 
All Candida spesies 26 7.6 14 4.9 
Total 342 100 288 100 
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Table 2.  Comparison of antimicrobial resistance rates of gram negative pathogens in ICU-acquired infec-
tions over the 2-year (2014 & 2016).
Pathogens Period 
Amikacin Ampicillin Gentamicin Imipenem
Piperacillin
/Tazobactam
Cefepime Cefotaxime
% p % p % p % p % p % p % p
E.coli
2014 30.8
,727
38.5
1,00
61.5
1,00
2016 39.1 43.5 65.2
Klebsiella 
pneumoniae
2014 35.5
,384
41.9
,000**
58.1
,160
2016 46.4 80.3 73.9
Pseudomonas 
aeruginosa
2014 44.2
,350
48.8
,652
65.1
,006**
2016 31.4 42.9 31.4
Acinetobacter 
baumanii
2014 62.9
1,00
69.7
,602
2016 63.0 74.0
Acinetobacter 
spp.
2014 77.4
,440
2016 66.7
Pseudomonas 
spp.
2014 40.0
1,00
40.0
1,00
2016 33.3 66.7
All Gram 
Negative 
Bacterias
2014 48.2
1,00
94.1
1,00a
62.3
,842
36.4
,395
56.4
,604
50.0
,000**
72.7
1,00
2016 48.2 100,0 63.3 44.4 60.1 91.9 70.0
 *: p<0.05; **: p<0.01.
Table 3.  Comparison of antibiotic resistance rates of gram-negative pathogens in ICU-acquired infections 
over the 2-year (2014 & 2016).
Pathogens Period 
Trimethoprim-
sulfamethoxazole
Meropenem Ciprofloxacin Ceftazidime Ceftriaxone Colistin
% p % p % p % p % p % p
E.coli
2014 69.2
,484a
69.2
1,00a
61.5
1,00
2016 52.2 65.2 65.2
Klebsiella 
pneumoniae
2014 58.1
1,00a
87.1
1,00a
58.1
,160
2016 58.0 87.0 73.9
Pseudomonas 
aeruginosa
2014 51.2
,108a
62.8
,254a
65.1
,006**
2016 31.4 48.6 31.4
Acinetobacter 
baumanii
2014 0.0
,017a*
2016 6.8
Acinetobacter 
spp.
2014
2016
Pseudomonas 
spp.
2014 40.0
,196a
40.0
1,00
2016 100.0 66.7
All Gram 
Negative 
Bacterias
2014 56.9
,457a
9.1
1,00a
54.7
,013a*
72.8
1,00a
56.4
,604
0.0
,001a**
2016 62.9 17.9 74.6 73.3 60.1 7.9
 *: p<0.05; **: p<0.01.
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Table 5.  Comparison of ICU-acquired infection rates for gram negative pathogens during the 2-year (2014 
& 2016).
Pathogens Period 
BSI RTI UTI SSI SSTI CNSI
% p % p % p % p % p % p
E.coli
2014 38.5
,475
7.7
,634
53.8
,310
0.0 0.0
,274
0.0
,508
2016 26.1 17.4 34.8 0.0 17.4 8.3
Klebsiella pneumoniae
2014 29.0
,191
41.9
1,00
25.8
,031*
3.2
,310
0.0
,568
0.0
,568
2016 43.5 42.0 8.7 0.0 2.9 2.9
Pseudomonas 
aeruginosa
2014 16.3
,538
60.5
,230
14.0
,119
7.0
,696
2.3
1,00
2016 11.1 75.0 2.8 11.1 0.0
Acinetobacter 
baumanii
2014 40.4
,000**
53.9
001**
2.2
1,00
2.2
,502
1.1
1,00
0.0
,202
2016 15.1 79.5 2.7 0.0 0.0 2.7
All Gram Negative 
Bacterias
2014 32.9
,432
50.6
,201
10.2
,643
3.1
,008**
3.1
,261
0.4
,058
2016 29.4 56.6 8.8 0.0 5.3 2.6
 *: p<0.05; **: p<0.01.
Table 4.  Comparison of antimicrobial resistance of gram-positive pathogens in ICU-acquired infections 
over the 2-year (2014 & 2016).
Pathogens Period 
Amikacin Linezolid Tetracycline
Trimethoprim /
sulfamethoxazole
Vancomycin Gentamicin Cefoxitin
% p % p % p % p % p % p % p
Stapylococcus 
aureus
2014 61.5
,717
100.0
,049*
2016 65.2 75.0
Enterococcus 
faecalis
2014 25.0
,608
58.1 50.0
,077
2016 42.9 73.9 0.0
CNS
2014 36.0
1,00a
65.1
,067
4.0
1,00
76.0
,031*
2016 36.8 31.4 0.0 42.1
Enterococcus 
faecium
2014 0.0
,464
2016 50.0
All Gram 
Positive 
Bacterias
2014 35.7
,128
2.4
1,00
43.4
,787a ,064
10.0
1,00
76.0
,031*
100.0
,049*
2016 69.2 0.0 36.8 42.1 75.0
 *: p<0.05; **: p<0.01.
The rates of ICU-acquired infections were com-
pared in gram-negative pathogens between 2014 
and 2016 (Table 5).
There was a significant decrease in the rate of de-
tection of A. baumanii as the pathogen microorga-
nism in BSI (40.4% -15.1%, p<0.01) and a significant 
increase in the rate of detection as the pathogen 
microorganism in RTI (53.9% -79.5%, p<0.01). A 
significant decrease in the rate of detection of K. 
pneumoniae as the pathogen microorganism in UTI 
was detected (25.8% -8.7%, p <0.05).
The rate of detection of all gram-negative bacteria 
as pathogen microorganism in SSI were significantly 
decreased (3.1%-0.0%, p<0.01). The decrease of 
in the rate of detection as the pathogen microor-
ganism in BSI and UTI and the increase in the rate 
of detection as an pathogen microorganism in RTI, 
SSTI and CNSI was not statistically significant.
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The distribution of ICU-acquired infection rates 
in gram-positive and fungal pathogens were shown 
between the years 2014 and 2016 (Table 6).
A significant increase in the rate of detection 
of all gram positive bacteria as the pathogen 
microorganism in SSI was found (0.0%-8.7%, 
p<0.05). The increase of in the rate of detection 
as a pathogen microorganism in RTI and the de-
crease of in the rate of detection as a pathogen 
microorganism in BSI and UTI was not statistically 
significant. 
A non-significant increase in BSI and a non-signi-
ficant decrease in UTI were detected in the rates of 
all Candida species and Candida albicans.
Discussion
Routine surveillance and reporting on prevalence 
of infection and antimicrobial resistance patterns 
of isolates among patients in ICUs are essential 
measurements to control misuse of certain anti-
microbial drugs and to reduce emergence of more 
resistant pathogens. Colistin resistance rates ran-
ging from 0.9% to 40.7% have been reported 
between 2001 and 2011, in many countries of 
Asia, Europe and the United States [12, 13]. Accor-
ding to this study, there was a significant increa-
se in colistin resistance rates among A. baumanii 
and all gram-negative bacteria isolates (p<0.05, 
p<0.01) (Table 3). First, the rates of colistin resis-
tance reported in A. baumanii were 5.9% in 1999 
in the Czech Republic. According to studies from 
Turkey, colistin resistance rates were reported to 
be ranged between 0% in 2014 and 0.6% in 2016 
[14, 15]. The primary cause of increased colistin 
resistance rates in our study was the significant 
especially for CIP, FEP, IMP, MEM, and TPZ which 
were frequently used in treatment of ICU-acqui-
red infections caused by gram-negative pathogens 
(Table 2, 3). 
Table 6.  Comparison of ICU-acquired infection rates in gram-positive and Candida microorganisms during 
the 2-year (2014 & 2016).
Microorganisms Period 
BSI RTI UTI SSI
% p % p % p % p
Stapylococcus aureus
2014 78.9
,253
21.1
,676
0.0
,387
2016 58.3 33.3 8.3
Enterococcus faecalis
2014 50.0
1,00
50.0
1,00
2016 57.1 42.9
CNS
2014 100.0
,444a
0.0
1,00
0.0
,444
2016 95.0 0.0 5.0
Enterococcus faecium
2014 100.0
1,00a
0.0
1,00
2016 83.3 16.7
All Gram Positive Bacterias
2014 80.3
,487
8.2
1,00
11.5
,754
0.0
,032*
2016 73.9 8.7 8.7 8.7
Candida spp.
2014 50.0
1,00
50.0
1,00
2016 57.1 42.9
Candida albicans
2014 66.7
,509
33.3
,509
2016 100.0 0.0
All Candida spesies
2014 60.0
,514
40.0
,514
2016 71.4 28.6
*: p<0.05
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In our hospital, many antibiotics including car-
bapenems are becoming useless in the treatment 
of multidrug resistant ICU-acquired A. baumannii 
infections. For this reason, colistin has been started 
to be used in empirical treatment. However, a re-
cently increase in colistin resistance to already exist 
multi-resistant gram-negative causing infections 
further complicates the selection of already limited 
treatment options. Studies from different countries 
have shown that increasing CIP, TPZ, and carba-
penem resistant in gram-negative bacteria isolates 
from intensive care units, as well as the increasing 
of community antimicrobial resistance rates, have 
affected empirical treatment choice [16, 17]. Com-
mon alternative antimicrobial treatment strategies 
need to be developed where the use of colistin 
should be limited for empirical treatment of pa-
tients of intensive care units as has been done in 
our hospital.
The increase in the detection rate of A. bauma-
nii as a pathogen causing RTIs was found signifi-
cant compared to other gram-negative pathogens 
(p<0.01) (Table 5). The average ventilator-associa-
ted pneumonia (VIP) infection rate also increased 
in 2016 compared to 2014 (VIP rate 2014: 7.12, 
2016: 7.45 per 1000 ventilator days). The efficacy 
of colistin treatment was noticed clearly in mul-
tidrug resistant A. baumanii pneumonias, espe-
cially among patients in ICU-acquired infections. 
Several studies have recommednded a combined 
treatment with colistin [18, 19]. In our hospital, 
the detection of multi-resistant A. baumanii in 
ICU-acquired infections resulted in increasing the 
use of colistin and conseguently a significant in-
crease in colistin resistance was detected. Incre-
asing infection control measures by improving 
isolation conditions, especially in our patients 
with RTIs, which were frequently infected with 
multi-drug resistant A. baumanii, may lead to a 
decrease in colistin resistance rates as has been 
demonstrated by other studies [20, 21]. In addi-
tion, we found a significant decrease in the rate of 
detection of all gram negative and gram positive 
bacteria as pathogens in BSI and UTI (Table 5, 6). 
When invasive device associated infections in ICU 
were examined, central venous catheter-related 
bloodstream infection rate (2.98%/2014 versus 
2.97%/2016:) and catheter-related urinary tract 
infection rate (0.97%/2014 versus 0.61%/2016) 
were also found to be slighlty decreased in our 
hospital. Several studies havefound that The inci-
dence of ICU-acquired infections, the distribution 
of pathogens and antibiotic resistance, and the 
frequency of infection from invasive devices are 
interrelated and should be analysed togather [22, 
23]. Therefore, a decrease in using invasive devices 
can reduce the frequency of acquired multidrug 
resistant bacteria [23].
This study demonstraded that gram-negative 
pathogens were more common in ICU-acquired in-
fections in 2016 than 2014 (Table 1). In addition, a 
significant decrease in the rate of detection of all 
gram-negative bacteria isolates in the SSI (p<0.01), 
and also a significant increase in the rates of all 
gram positive bacteria in the SSI (p<0.05) was ob-
served (Table 5). The reason for the increase of SSI 
caused by gram-positive pathogens is related to pa-
tients who were admitted to the CVS and gyneco-
logy ICUs. Therefore, it is also important to choose 
empiric antibiotherapy which are effective against 
gram-positive.
Conclusion
In conclusion, increased antimicrobial resistance, 
especially increased colistin resistance rates in ICU-
infected patients, necessitates the creation of new 
strategies in empirical therapy. Reporting of anti-
microbial resistance profiles of recovered patho-
gens in ICUs is recommended guide for correct 
antimicrobial management and control nosocomial 
infection.
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